Symvivo is a clinical-stage biotechnology company advancing a proprietary platform for the site-specific delivery of genes for the treatment and prevention of life-threatening diseases. Symvivo’s bacTRL™ platform technology delivers plasmid DNA, both orally and through IV administration, that enables a patient’s own cells to produce biologics. Symvivo is advancing therapeutics in the area of oral vaccines, oncology, immunology, and biologics.